Meghan Elizabeth Sise, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Kidney Injury | 34 | 2024 | 1923 | 6.260 |
Why?
|
| Hepatitis C | 25 | 2023 | 1579 | 5.260 |
Why?
|
| Antiviral Agents | 32 | 2024 | 3048 | 4.280 |
Why?
|
| Renal Insufficiency, Chronic | 23 | 2024 | 2254 | 4.170 |
Why?
|
| Hepatitis C, Chronic | 15 | 2023 | 1027 | 3.460 |
Why?
|
| Kidney Failure, Chronic | 14 | 2023 | 2478 | 2.820 |
Why?
|
| Nephritis, Interstitial | 7 | 2024 | 155 | 2.650 |
Why?
|
| Hepacivirus | 17 | 2023 | 1330 | 2.260 |
Why?
|
| Glomerular Filtration Rate | 16 | 2024 | 2181 | 2.240 |
Why?
|
| Kidney Transplantation | 14 | 2021 | 4240 | 1.910 |
Why?
|
| Kidney | 24 | 2024 | 7034 | 1.830 |
Why?
|
| Adenosine Monophosphate | 4 | 2024 | 231 | 1.810 |
Why?
|
| Alanine | 4 | 2024 | 608 | 1.660 |
Why?
|
| Renal Insufficiency | 3 | 2023 | 808 | 1.590 |
Why?
|
| Creatinine | 12 | 2024 | 1897 | 1.520 |
Why?
|
| Thyroiditis | 2 | 2021 | 86 | 1.480 |
Why?
|
| Lipocalins | 9 | 2012 | 161 | 1.250 |
Why?
|
| Acute-Phase Proteins | 9 | 2012 | 250 | 1.220 |
Why?
|
| Kidney Diseases | 7 | 2019 | 2092 | 1.170 |
Why?
|
| Cryoglobulinemia | 2 | 2018 | 84 | 1.080 |
Why?
|
| Proteinuria | 5 | 2023 | 604 | 1.080 |
Why?
|
| Benzimidazoles | 4 | 2021 | 858 | 1.040 |
Why?
|
| Cystatin C | 2 | 2024 | 270 | 1.020 |
Why?
|
| Renal Dialysis | 7 | 2022 | 1796 | 0.990 |
Why?
|
| Prednisone | 2 | 2021 | 1565 | 0.990 |
Why?
|
| Tissue Donors | 10 | 2024 | 2334 | 0.950 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 3 | 2017 | 335 | 0.910 |
Why?
|
| Neoplasms | 14 | 2024 | 22125 | 0.870 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2022 | 1468 | 0.800 |
Why?
|
| Aminoisobutyric Acids | 2 | 2020 | 39 | 0.770 |
Why?
|
| Nephrology | 2 | 2022 | 263 | 0.750 |
Why?
|
| Hepatitis B | 3 | 2023 | 704 | 0.740 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2022 | 1405 | 0.740 |
Why?
|
| Hyperkalemia | 1 | 2023 | 233 | 0.730 |
Why?
|
| Hypokalemia | 1 | 2021 | 153 | 0.720 |
Why?
|
| Fluorenes | 2 | 2021 | 157 | 0.710 |
Why?
|
| Graft vs Host Disease | 3 | 2023 | 3026 | 0.700 |
Why?
|
| Nephritis | 1 | 2021 | 147 | 0.690 |
Why?
|
| Melanoma | 4 | 2024 | 5694 | 0.690 |
Why?
|
| Leucine | 2 | 2020 | 547 | 0.670 |
Why?
|
| Glomerulonephritis | 2 | 2020 | 333 | 0.670 |
Why?
|
| Cyclopropanes | 2 | 2020 | 432 | 0.670 |
Why?
|
| Proline | 2 | 2020 | 455 | 0.660 |
Why?
|
| Lactams, Macrocyclic | 2 | 2020 | 318 | 0.660 |
Why?
|
| Quinoxalines | 2 | 2020 | 296 | 0.650 |
Why?
|
| Sarcopenia | 1 | 2024 | 370 | 0.640 |
Why?
|
| Hyponatremia | 1 | 2021 | 279 | 0.640 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2020 | 109 | 0.640 |
Why?
|
| Donor Selection | 5 | 2021 | 232 | 0.620 |
Why?
|
| Retrospective Studies | 40 | 2024 | 80673 | 0.620 |
Why?
|
| Albuminuria | 3 | 2019 | 656 | 0.620 |
Why?
|
| Humans | 120 | 2024 | 761098 | 0.610 |
Why?
|
| Ribavirin | 3 | 2016 | 394 | 0.590 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2023 | 5667 | 0.570 |
Why?
|
| Uridine Monophosphate | 1 | 2017 | 66 | 0.560 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2024 | 2054 | 0.560 |
Why?
|
| Proto-Oncogene Proteins | 9 | 2012 | 4510 | 0.560 |
Why?
|
| Kidney Neoplasms | 3 | 2022 | 4251 | 0.540 |
Why?
|
| Serologic Tests | 1 | 2018 | 381 | 0.540 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2023 | 2549 | 0.490 |
Why?
|
| Tissue and Organ Procurement | 3 | 2024 | 962 | 0.490 |
Why?
|
| Aged | 41 | 2024 | 169266 | 0.460 |
Why?
|
| Adiposity | 1 | 2024 | 1879 | 0.450 |
Why?
|
| Middle Aged | 49 | 2024 | 220835 | 0.440 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2022 | 1878 | 0.420 |
Why?
|
| Male | 58 | 2024 | 360675 | 0.420 |
Why?
|
| RNA, Viral | 2 | 2020 | 2839 | 0.410 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3094 | 0.410 |
Why?
|
| Virus Diseases | 1 | 2018 | 716 | 0.400 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3216 | 0.400 |
Why?
|
| Interferon-alpha | 2 | 2015 | 907 | 0.400 |
Why?
|
| Urinary Bladder Neck Obstruction | 1 | 2011 | 80 | 0.380 |
Why?
|
| Urethral Obstruction | 1 | 2011 | 55 | 0.380 |
Why?
|
| Rheumatic Diseases | 1 | 2018 | 649 | 0.380 |
Why?
|
| Female | 57 | 2024 | 392458 | 0.380 |
Why?
|
| Protease Inhibitors | 1 | 2015 | 752 | 0.380 |
Why?
|
| Sulfonamides | 2 | 2020 | 1977 | 0.380 |
Why?
|
| Viremia | 4 | 2023 | 707 | 0.370 |
Why?
|
| Thrombotic Microangiopathies | 2 | 2023 | 123 | 0.360 |
Why?
|
| Oligopeptides | 1 | 2015 | 1178 | 0.330 |
Why?
|
| Cause of Death | 1 | 2020 | 3688 | 0.330 |
Why?
|
| Pyrazoles | 1 | 2020 | 2010 | 0.330 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 2316 | 0.320 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2021 | 2223 | 0.320 |
Why?
|
| Survival Analysis | 1 | 2021 | 10083 | 0.320 |
Why?
|
| Skin Neoplasms | 4 | 2024 | 5809 | 0.320 |
Why?
|
| HIV Infections | 3 | 2023 | 17349 | 0.300 |
Why?
|
| Positron-Emission Tomography | 3 | 2024 | 6585 | 0.300 |
Why?
|
| Hematologic Neoplasms | 1 | 2020 | 1895 | 0.300 |
Why?
|
| Drug Therapy, Combination | 6 | 2022 | 6305 | 0.290 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 5662 | 0.290 |
Why?
|
| Treatment Outcome | 18 | 2024 | 64670 | 0.280 |
Why?
|
| Gout | 2 | 2024 | 621 | 0.270 |
Why?
|
| Cisplatin | 2 | 2024 | 1651 | 0.270 |
Why?
|
| Infant, Premature, Diseases | 1 | 2012 | 710 | 0.270 |
Why?
|
| Ovarian Neoplasms | 1 | 2023 | 4853 | 0.270 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2021 | 3163 | 0.260 |
Why?
|
| Immunotherapy | 5 | 2021 | 4642 | 0.260 |
Why?
|
| Adult | 32 | 2024 | 221083 | 0.260 |
Why?
|
| Urinalysis | 3 | 2017 | 368 | 0.260 |
Why?
|
| Hospitalization | 3 | 2024 | 10712 | 0.260 |
Why?
|
| Bacteremia | 1 | 2012 | 978 | 0.250 |
Why?
|
| Renal Replacement Therapy | 3 | 2024 | 281 | 0.250 |
Why?
|
| Liver Cirrhosis | 6 | 2020 | 1932 | 0.230 |
Why?
|
| Hydroxylamines | 1 | 2023 | 39 | 0.220 |
Why?
|
| Ribose | 1 | 2023 | 63 | 0.220 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2024 | 2025 | 0.220 |
Why?
|
| Antineoplastic Agents | 2 | 2023 | 13630 | 0.220 |
Why?
|
| Kidney Function Tests | 2 | 2024 | 680 | 0.220 |
Why?
|
| Cohort Studies | 14 | 2024 | 41486 | 0.210 |
Why?
|
| Opioid-Related Disorders | 1 | 2018 | 2164 | 0.210 |
Why?
|
| Baclofen | 1 | 2023 | 120 | 0.210 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2024 | 12145 | 0.210 |
Why?
|
| Hepatitis B virus | 2 | 2023 | 527 | 0.200 |
Why?
|
| Sulfonylurea Compounds | 1 | 2024 | 219 | 0.200 |
Why?
|
| Digoxin | 1 | 2023 | 246 | 0.200 |
Why?
|
| Disease Progression | 6 | 2022 | 13506 | 0.200 |
Why?
|
| Hypertension, Pulmonary | 1 | 2013 | 1585 | 0.200 |
Why?
|
| Taste Disorders | 1 | 2022 | 38 | 0.200 |
Why?
|
| Aged, 80 and over | 11 | 2024 | 58946 | 0.190 |
Why?
|
| Pyrrolidines | 2 | 2020 | 339 | 0.190 |
Why?
|
| Lung | 1 | 2020 | 9979 | 0.190 |
Why?
|
| Ritonavir | 1 | 2023 | 329 | 0.190 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2023 | 426 | 0.190 |
Why?
|
| Sepsis | 2 | 2012 | 2586 | 0.190 |
Why?
|
| Prognosis | 7 | 2024 | 29672 | 0.180 |
Why?
|
| Uric Acid | 2 | 2024 | 806 | 0.180 |
Why?
|
| Micropore Filters | 1 | 2020 | 22 | 0.180 |
Why?
|
| Electrolytes | 1 | 2021 | 274 | 0.180 |
Why?
|
| Risk Factors | 15 | 2024 | 74219 | 0.180 |
Why?
|
| BK Virus | 1 | 2021 | 120 | 0.180 |
Why?
|
| Lupus Nephritis | 1 | 2024 | 317 | 0.180 |
Why?
|
| AIDS-Associated Nephropathy | 2 | 2011 | 34 | 0.180 |
Why?
|
| Oximes | 1 | 2022 | 303 | 0.180 |
Why?
|
| Carboplatin | 1 | 2023 | 793 | 0.170 |
Why?
|
| Vancomycin | 1 | 2023 | 503 | 0.170 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2020 | 1812 | 0.170 |
Why?
|
| Disease Management | 3 | 2020 | 2508 | 0.170 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2020 | 161 | 0.170 |
Why?
|
| Polyomavirus Infections | 1 | 2021 | 192 | 0.160 |
Why?
|
| Pneumonia | 2 | 2022 | 2142 | 0.160 |
Why?
|
| Pyrimidinones | 1 | 2022 | 385 | 0.160 |
Why?
|
| Olfaction Disorders | 1 | 2022 | 224 | 0.160 |
Why?
|
| Kidney Glomerulus | 1 | 2021 | 567 | 0.160 |
Why?
|
| Anti-HIV Agents | 1 | 2015 | 4526 | 0.160 |
Why?
|
| Heart Failure | 1 | 2023 | 11701 | 0.160 |
Why?
|
| Adrenal Gland Diseases | 1 | 2020 | 141 | 0.160 |
Why?
|
| Pericardial Effusion | 1 | 2021 | 247 | 0.160 |
Why?
|
| Urogenital Neoplasms | 1 | 2020 | 131 | 0.160 |
Why?
|
| Incidence | 6 | 2024 | 21357 | 0.160 |
Why?
|
| Water-Electrolyte Balance | 1 | 2020 | 325 | 0.160 |
Why?
|
| Tumor Virus Infections | 1 | 2021 | 435 | 0.160 |
Why?
|
| International Classification of Diseases | 1 | 2024 | 913 | 0.160 |
Why?
|
| Oxidation-Reduction | 1 | 2024 | 2227 | 0.150 |
Why?
|
| Injections, Intravenous | 1 | 2020 | 1376 | 0.150 |
Why?
|
| Amides | 1 | 2020 | 449 | 0.140 |
Why?
|
| Reperfusion Injury | 1 | 2024 | 1026 | 0.140 |
Why?
|
| Drug Combinations | 2 | 2020 | 2048 | 0.140 |
Why?
|
| Infant, Very Low Birth Weight | 2 | 2010 | 407 | 0.140 |
Why?
|
| Myositis | 1 | 2020 | 270 | 0.140 |
Why?
|
| Time Factors | 7 | 2024 | 39953 | 0.140 |
Why?
|
| Survival Rate | 3 | 2020 | 12727 | 0.140 |
Why?
|
| Pyridones | 1 | 2022 | 809 | 0.130 |
Why?
|
| Sodium | 1 | 2021 | 1589 | 0.130 |
Why?
|
| Biopsy | 3 | 2018 | 6781 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 3 | 2020 | 7405 | 0.130 |
Why?
|
| Interleukin-2 | 1 | 2023 | 1891 | 0.130 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2020 | 328 | 0.130 |
Why?
|
| Imidazoles | 1 | 2022 | 1173 | 0.130 |
Why?
|
| Paclitaxel | 1 | 2023 | 1730 | 0.130 |
Why?
|
| Drug Administration Schedule | 2 | 2021 | 4849 | 0.130 |
Why?
|
| Patient Care Management | 1 | 2018 | 302 | 0.120 |
Why?
|
| Hypothyroidism | 1 | 2020 | 668 | 0.120 |
Why?
|
| Postoperative Complications | 1 | 2017 | 15634 | 0.120 |
Why?
|
| Nitriles | 1 | 2020 | 971 | 0.120 |
Why?
|
| Proton Pump Inhibitors | 1 | 2019 | 534 | 0.120 |
Why?
|
| Immunologic Factors | 2 | 2021 | 1589 | 0.120 |
Why?
|
| Drug Monitoring | 1 | 2020 | 961 | 0.120 |
Why?
|
| Pyrazines | 1 | 2020 | 1202 | 0.110 |
Why?
|
| Comorbidity | 2 | 2020 | 10514 | 0.110 |
Why?
|
| Hypoglycemic Agents | 2 | 2024 | 3086 | 0.110 |
Why?
|
| Propensity Score | 1 | 2021 | 1913 | 0.110 |
Why?
|
| Educational Status | 1 | 2021 | 2510 | 0.110 |
Why?
|
| Chemokine CXCL9 | 2 | 2024 | 135 | 0.110 |
Why?
|
| Radiography, Thoracic | 1 | 2020 | 1303 | 0.110 |
Why?
|
| Respiration, Artificial | 1 | 2024 | 2630 | 0.110 |
Why?
|
| Thiosulfates | 1 | 2013 | 53 | 0.110 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2015 | 696 | 0.110 |
Why?
|
| Acute Disease | 2 | 2024 | 7240 | 0.110 |
Why?
|
| Heparin | 1 | 2020 | 1632 | 0.110 |
Why?
|
| Nephrotic Syndrome | 1 | 2017 | 382 | 0.110 |
Why?
|
| Lung Neoplasms | 3 | 2022 | 13382 | 0.100 |
Why?
|
| Interdisciplinary Communication | 1 | 2018 | 928 | 0.100 |
Why?
|
| Drug Resistance, Viral | 1 | 2018 | 862 | 0.100 |
Why?
|
| Informed Consent | 1 | 2019 | 1007 | 0.100 |
Why?
|
| Myocarditis | 1 | 2020 | 792 | 0.100 |
Why?
|
| Pandemics | 3 | 2022 | 8663 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 10213 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2022 | 11732 | 0.100 |
Why?
|
| Chelating Agents | 1 | 2013 | 383 | 0.100 |
Why?
|
| Critical Illness | 2 | 2023 | 2709 | 0.100 |
Why?
|
| Calciphylaxis | 1 | 2013 | 130 | 0.090 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 1664 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 10755 | 0.090 |
Why?
|
| Survivors | 1 | 2021 | 2369 | 0.090 |
Why?
|
| Heart Transplantation | 1 | 2024 | 3258 | 0.090 |
Why?
|
| Cardiac Output | 1 | 2013 | 831 | 0.090 |
Why?
|
| Physician's Role | 1 | 2017 | 916 | 0.090 |
Why?
|
| Nephrons | 1 | 2012 | 168 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2021 | 2981 | 0.090 |
Why?
|
| Massachusetts | 2 | 2021 | 8836 | 0.090 |
Why?
|
| Double-Blind Method | 1 | 2024 | 12341 | 0.090 |
Why?
|
| Autoimmunity | 1 | 2018 | 1354 | 0.090 |
Why?
|
| Logistic Models | 4 | 2021 | 13254 | 0.090 |
Why?
|
| Risk Assessment | 3 | 2024 | 24013 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2024 | 20600 | 0.080 |
Why?
|
| Cytokines | 2 | 2023 | 7386 | 0.080 |
Why?
|
| Genotype | 3 | 2020 | 12983 | 0.080 |
Why?
|
| Mice, Knockout | 1 | 2024 | 14393 | 0.080 |
Why?
|
| Boston | 1 | 2021 | 9324 | 0.070 |
Why?
|
| Critical Care | 1 | 2020 | 2690 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2020 | 3026 | 0.070 |
Why?
|
| Anticoagulants | 2 | 2020 | 4795 | 0.070 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2023 | 3609 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 5494 | 0.070 |
Why?
|
| Azotemia | 2 | 2020 | 8 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 1 | 2020 | 2896 | 0.060 |
Why?
|
| United States | 4 | 2022 | 72337 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2020 | 4021 | 0.060 |
Why?
|
| Young Adult | 4 | 2020 | 59199 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2024 | 18217 | 0.060 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2024 | 153 | 0.060 |
Why?
|
| Prospective Studies | 6 | 2020 | 54419 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2017 | 5971 | 0.060 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2024 | 89 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 5318 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 12975 | 0.050 |
Why?
|
| Vitamins | 2 | 2022 | 1634 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 26068 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2015 | 9648 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 7400 | 0.050 |
Why?
|
| Mitochondria | 1 | 2015 | 3620 | 0.050 |
Why?
|
| Bilirubin | 1 | 2023 | 435 | 0.050 |
Why?
|
| Prevalence | 2 | 2022 | 15717 | 0.050 |
Why?
|
| Brain Death | 1 | 2024 | 357 | 0.050 |
Why?
|
| Endothelium, Vascular | 1 | 2013 | 4421 | 0.050 |
Why?
|
| Early Diagnosis | 2 | 2020 | 1187 | 0.050 |
Why?
|
| Nephrosis, Lipoid | 1 | 2020 | 45 | 0.040 |
Why?
|
| Contrast Media | 2 | 2024 | 5311 | 0.040 |
Why?
|
| Myoglobin | 1 | 2020 | 159 | 0.040 |
Why?
|
| Emergency Service, Hospital | 2 | 2012 | 7873 | 0.040 |
Why?
|
| Follow-Up Studies | 4 | 2015 | 39121 | 0.040 |
Why?
|
| Hypertension | 1 | 2020 | 8537 | 0.040 |
Why?
|
| Heart | 1 | 2013 | 4431 | 0.040 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2020 | 87 | 0.040 |
Why?
|
| Factor Xa | 1 | 2020 | 166 | 0.040 |
Why?
|
| Rhabdomyolysis | 1 | 2020 | 152 | 0.040 |
Why?
|
| Predictive Value of Tests | 3 | 2012 | 15308 | 0.040 |
Why?
|
| Equipment Contamination | 1 | 2020 | 182 | 0.040 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2020 | 382 | 0.040 |
Why?
|
| Equipment Failure Analysis | 1 | 2020 | 846 | 0.040 |
Why?
|
| Obesity | 1 | 2020 | 12937 | 0.040 |
Why?
|
| Mutation | 1 | 2022 | 30006 | 0.040 |
Why?
|
| Ascorbic Acid | 1 | 2020 | 654 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2024 | 36418 | 0.030 |
Why?
|
| Adolescent | 4 | 2020 | 88271 | 0.030 |
Why?
|
| Hospital Mortality | 2 | 2020 | 5296 | 0.030 |
Why?
|
| Transplantation Conditioning | 1 | 2023 | 1591 | 0.030 |
Why?
|
| Natural Language Processing | 1 | 2024 | 1166 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2023 | 2327 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2020 | 1436 | 0.030 |
Why?
|
| Blood Coagulation | 1 | 2020 | 1156 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 11856 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2009 | 9317 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2011 | 22157 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2016 | 6343 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2024 | 3696 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2024 | 3114 | 0.030 |
Why?
|
| ROC Curve | 2 | 2011 | 3582 | 0.030 |
Why?
|
| Cation Exchange Resins | 1 | 2012 | 19 | 0.030 |
Why?
|
| Infection Control | 1 | 2020 | 983 | 0.030 |
Why?
|
| Injections, Intralesional | 1 | 2013 | 280 | 0.030 |
Why?
|
| North America | 1 | 2016 | 1281 | 0.030 |
Why?
|
| Chromatography, Ion Exchange | 1 | 2012 | 294 | 0.030 |
Why?
|
| Chromatography, Gel | 1 | 2012 | 642 | 0.020 |
Why?
|
| Research | 1 | 2020 | 1975 | 0.020 |
Why?
|
| Forecasting | 1 | 2020 | 2928 | 0.020 |
Why?
|
| Cross Infection | 1 | 2020 | 1422 | 0.020 |
Why?
|
| Graft Survival | 1 | 2021 | 3841 | 0.020 |
Why?
|
| Pregnancy | 1 | 2012 | 29872 | 0.020 |
Why?
|
| Sensitivity and Specificity | 3 | 2011 | 14676 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2024 | 3416 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2015 | 1187 | 0.020 |
Why?
|
| Inpatients | 1 | 2021 | 2545 | 0.020 |
Why?
|
| Europe | 1 | 2016 | 3422 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 15845 | 0.020 |
Why?
|
| Mice | 3 | 2024 | 81324 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2023 | 12743 | 0.020 |
Why?
|
| New York City | 1 | 2010 | 730 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 8519 | 0.020 |
Why?
|
| Remission Induction | 1 | 2013 | 2392 | 0.020 |
Why?
|
| Atrophy | 1 | 2012 | 1633 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2024 | 4813 | 0.020 |
Why?
|
| Length of Stay | 1 | 2020 | 6420 | 0.020 |
Why?
|
| Viral Load | 1 | 2015 | 3328 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2024 | 5841 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 3419 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2024 | 22129 | 0.020 |
Why?
|
| New York | 1 | 2008 | 875 | 0.020 |
Why?
|
| Fibrosis | 1 | 2012 | 2051 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 3803 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2012 | 2189 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 5033 | 0.010 |
Why?
|
| Mass Screening | 1 | 2020 | 5425 | 0.010 |
Why?
|
| Animals | 3 | 2024 | 168083 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 12058 | 0.010 |
Why?
|
| Reference Values | 1 | 2009 | 4922 | 0.010 |
Why?
|
| Gestational Age | 1 | 2010 | 3577 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2010 | 4111 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2016 | 7969 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 2010 | 26187 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 14607 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 15513 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 9518 | 0.010 |
Why?
|
| Models, Biological | 1 | 2012 | 9455 | 0.010 |
Why?
|
| Sex Factors | 1 | 2009 | 10552 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 17889 | 0.010 |
Why?
|